Gottsegen National Cardiovascular Center
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Gottsegen National Cardiovascular Center’s Adult Cardiac Surgery department is advancing research in cardiovascular diseases, focusing on conditions such as heart failure, myocardial infarction, coronary artery disease, and hypertrophic cardiomyopathy. Ongoing studies aim to test innovative therapies, improve risk assessment, and enhance outcomes for patients with complex cardiac pathology.
- Evaluation of novel treatments for acute heart failure and reduced ejection fraction
- Investigation of therapies targeting elevated lipoprotein(a) to lower cardiovascular risk
- Trials assessing revascularization strategies and residual ischemic burden in coronary bypass surgery
- Studies of combination drugs to reduce major adverse cardiovascular events in patients with diabetes and hypertension
- Research on agents that improve myocardial structure in obstructive hypertrophic cardiomyopathy
These programs reflect the center’s commitment to translating cutting‑edge science into safer, more effective care for patients across Hungary and Europe.
Respiratory Tract Diseases
Within the same facility, investigators are dedicated to respiratory tract diseases, particularly pulmonary arterial hypertension (PAH). Clinical work includes testing triple‑therapy regimens, assessing long‑term safety of emerging agents, and extending research to pediatric populations to improve survival and quality of life.
- Comparison of initial triple therapy versus double oral therapy in adult PAH patients
- Long‑term safety extensions of oral agents such as ralinepag for PAH
- Pediatric studies evaluating preservative‑free treprostinil and macitentan
- Platform trials monitoring safety and tolerability of various PAH interventions
- Exploration of new pathways to reduce disease progression in PAH group I
The site’s multidisciplinary approach leverages its cardiac surgery expertise to address the intersecting challenges of heart and lung vascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC7trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gottsegen National Cardiovascular Center
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.